VENTANA® HER2 Dual ISH DNA Probe Cocktail


IVD For in vitro diagnostic use.
HER2 DUAL ISH thumbnail image
Optimized with new oligo probes, the VENTANA HER2 Dual ISH assay delivers clear, confident reads

The new VENTANA HER2 Dual ISH DNA Probe Cocktail assay is a fully automated, ready-to-use brightfield solution for determining HER2 gene status. VENTANA HER2 Dual ISH helps identify breast cancer patients eligible for treatment with HER2-targeted personalized therapies.


Increased performance

  • Oligo probes and new detection kits
  • High first pass rates1


Easily interpreted using brightfield microscopy2

  • Allows for interpretation within the context of tissue morphology
  • Identifies tumor heterogeneity
  • Produces an archivable result


Robust & reproducible

  • Highly concordant with FISH1
  • Highly reproducible between laboratories & pathologists1


Diagnostic confidence

  • Fully automated solution with fast turnaround time
  • Widely adopted breast cancer portfolio with high clinical utility

Importance of HER2 in oncology - Breast cancer

HER2 breast cancer icon

Breast cancer comprises 24% of all female cancers and is estimated to claim the lives of more than 600,000 globally each year.3

HER2 breast cancer group icon

15-20% of breast cancers overexpress HER2 and are eligible for HER2-targeted therapies, which are proven to improve outcomes.4

HER2 cancer companion therapies icon

Demonstration of HER2 gene amplification and/or protein overexpression is essential for selecting patients for trastuzumab therapy.

Deliver diagnostic confidence

Multiple guidelines, including NCCN and CAP/ASCO5,6, recommend the evaluation of human epidermal growth factor receptor 2 (HER2) protein expression by immunohistochemistry (IHC) assay for breast cancer specimens. Depending on the IHC result, a reflex test should be performed-using in situ hybridization (ISH).

The VENTANA HER2 Dual ISH DNA Probe Cocktail is intended to determine HER2 gene status by enumeration of the ratio of the HER2 gene to Chromosome 17 by light microscopy. This ready-to-use assay is optimized for use on formalin-fixed, paraffin-embedded human breast carcinoma tissue specimens with the VENTANA Silver ISH DNP Detection Kit and the VENTANA Red ISH DIG Detection Kit, on the fully-automated BenchMark ULTRA instruments.

The VENTANA HER2 Dual ISH DNA Probe Cocktail is indicated as an aid in the assessment of patients for whom Herceptin (trastuzumab) is being considered.

Provides morphological context for the pathologist
  • Signals visualized at lower magnification, allowing pathologist to easily scan the entire tissue section to identify invasive carcinoma and tumor heterogeneity
  • Counterstained with Hematoxylin II like IHC slides so morphologic features are preserved and visible. Allows distinction between invasive and in situ carcinoma, identification of normal cells and easy comparison to H&E slide and IHC slides
  • Normal cells provide a same slide internal control of the staining process so you can be confident of the results
  • Archivable results
  • Signals do not fade over time
Why brightfield is better
  • No need for fluorescent microscope/oil and darkroom
  • Fits in pathologists’ regular workflow at brightfield scope
  • Can be read alongside/at same time as H&E and other breast panel markers on the same case for easy comparison and correlation of findings
  • No interference from tissue auto fluorescence or tissue marking dyes
  • Avoids need for oil immersion lens



  1. Ventana Product Document Library. Package Insert, VENTANA HER2 Dual ISH DNA Probe Cocktail.
  2. Ventana Product Document Library. Interpretation Guide for VENTANA HER2 Dual ISH DNA Probe Cocktail assay; Staining for Breast Carcinoma.
  3.  Globocan 2018. Global Cancer Observatory, International Agency for Research on Cancer (
  4.  Wolff AC, Hicks D, Hammond E. ASCO/CAP Clinical Practice Guideline Update. J Clin Oncol.2013;31(31):3997-4013.
  5. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. Wolff AC,  Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P, Hanna W, Jenkins RB, Press MF, Spears PA, Vance GH, Viale G, McShane LM, Dowsett M. J Clin Oncol. 2018 Jul 10;36(20):2105-2122.
  6. NCCN Guidelines Version 1.2018. NCCN Clinical Practice Guidelines in Oncology Breast Cancer.



Detailed Specifications

Ordering Information

Compatible Instruments


    Technical Documents

    Access Material Data Sheets, Certificates of Analysis, and other product documentation.

    After clicking below, you will be redirected to eLabDoc, where you can choose your local country.
    error errorMessage
    Sorry, we couldn't find the content you are looking for
    Please try again later